Precision Biosciences (DTIL) Other Non-Current Liabilities (2020 - 2026)
Precision Biosciences (DTIL) posted quarterly Other Non-Current Liabilities of $22.8 million for Q1 2026, up 128.02% year-over-year from $10.0 million in Q1 2025, and up 45.28% quarter-over-quarter from $15.7 million in Q4 2025.
Precision Biosciences (DTIL) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Other Non-Current Liabilities for 7 consecutive years, with $22.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 128.02% year-over-year to $22.8 million; the TTM figure through Mar 2026 stood at $22.8 million (up 128.02% YoY), while the FY2025 annual figure was $15.7 million, up 56.95% from the prior year.
- Other Non-Current Liabilities climbed to $22.8 million in Q1 2026 per DTIL's latest filing, from $15.7 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $22.8 million in Q1 2026 and bottomed at $34000.0 in Q1 2022.
- Historically, Other Non-Current Liabilities has averaged $8.6 million across 5 years, with a median of $10.0 million in 2022.
- Annual changes were most pronounced in 2023 — Other Non-Current Liabilities surged 29311.76% — and 2024, when it sank 98.12%.
- Precision Biosciences' Other Non-Current Liabilities stood at $201000.0 in 2022, then plunged by 36.32% to $128000.0 in 2023, then surged by 7712.5% to $10.0 million in 2024, then soared by 56.95% to $15.7 million in 2025, then surged by 45.28% to $22.8 million in 2026.
- Business Quant data shows DTIL's Other Non-Current Liabilities at $22.8 million in Q1 2026, $15.7 million in Q4 2025, and $227000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Precision Biosciences | 228.31 Mn | 140.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36.69 Mn |
| Mar 31, 2026 | 22.80 Mn |
| Dec 31, 2025 | 15.70 Mn |
| Sep 30, 2025 | 227,000.00 |
| Jun 30, 2025 | 10.00 Mn |
| Mar 31, 2025 | 10.00 Mn |
| Dec 31, 2024 | 10.00 Mn |
| Sep 30, 2024 | 188,000.00 |
| Jun 30, 2024 | 14.26 Mn |
| Mar 31, 2024 | 22.02 Mn |
| Dec 31, 2023 | 128,000.00 |
| Sep 30, 2023 | 10.00 Mn |
| Jun 30, 2023 | 10.00 Mn |
| Mar 31, 2023 | 10.00 Mn |
| Dec 31, 2022 | 201,000.00 |
| Sep 30, 2022 | 217,000.00 |
| Jun 30, 2022 | 10.00 Mn |
| Mar 31, 2022 | 34,000.00 |
| Dec 31, 2021 | 44,000.00 |
| Sep 30, 2021 | 10.00 Mn |